Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by IainCaimbeulon Jul 15, 2024 11:28pm
67 Views
Post# 36134070

RE:RE:Now in month four of cease trading order...

RE:RE:Now in month four of cease trading order...
LithLover wrote: This is all on Tripp and is inability to execute. 

Look at the patents, the Board of Directors, the Scientific Board, the Drs of Ongology at Care Oncology, Ichor Blood and the warrant holders and finaciers.  Many people saw the potential of this product but Tripp's lack of business acumen and his inability to sell killed this company. 

Tripp needs to be replaced immediately and maybe the company has patents/assets worth something for a small buyout to give something back to shareholders.

Finally an intelligent response.
<< Previous
Bullboard Posts
Next >>